
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5637942/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The association between physical activity time and neuropathy in longstanding type 1 diabetes: A cross-sectional analysis of the Canadian study of longevity in type 1 diabetes. Journal of Diabetes and Its Complications, 2022, 36, 108134.	2.3	5
2	Orthostatic blood pressure changes and diabetes duration. Journal of Diabetes and Its Complications, 2022, 36, 108169.	2.3	2
3	Empagliflozin add-on therapy to closed-loop insulin delivery in type 1 diabetes: a 2 × 2 factorial randomized crossover trial. Nature Medicine, 2022, 28, 1269-1276.	30.7	20
4	Baseline omega-3 level is associated with nerve regeneration following 12-months of omega-3 nutrition therapy in patients with type 1 diabetes. Journal of Diabetes and Its Complications, 2021, 35, 107798.	2.3	10
5	Changes in Cardiovascular Biomarkers Associated With the Sodium–Glucose Cotransporter 2 (SGLT2) Inhibitor Ertugliflozin in Patients With Chronic Kidney Disease and Type 2 Diabetes. Diabetes Care, 2021, 44, e45-e47.	8.6	22
6	The complex association between pain and neuropathy. Muscle and Nerve, 2021, 63, 538-545.	2.2	0
7	Reducing the need for carbohydrate counting in type 1 diabetes using closedâ€loop automated insulin delivery (artificial pancreas) and empagliflozin: A randomized, controlled, nonâ€inferiority, crossover pilot trial. Diabetes, Obesity and Metabolism, 2021, 23, 1272-1281.	4.4	19
8	Vasopressin associated with renal vascular resistance in adults with longstanding type 1 diabetes with and without diabetic kidney disease. Journal of Diabetes and Its Complications, 2021, 35, 107807.	2.3	8
9	Discoveries from the study of longstanding type 1 diabetes. Diabetologia, 2021, 64, 1189-1200.	6.3	12
10	Relationships between inflammation, hemodynamic function and RAAS in longstanding type 1 diabetes and diabetic kidney disease. Journal of Diabetes and Its Complications, 2021, 35, 107880.	2.3	8
11	Corneal Confocal Microscopy Predicts the Development of Diabetic Neuropathy: A Longitudinal Diagnostic Multinational Consortium Study. Diabetes Care, 2021, 44, 2107-2114.	8.6	28
12	Clinical profile and impact of comorbidities in patients with veryâ€lateâ€onset myasthenia gravis. Muscle and Nerve, 2021, 64, 462-466.	2.2	13
13	Changes in plasma and urine metabolites associated with empagliflozin in patients with type 1 diabetes. Diabetes, Obesity and Metabolism, 2021, 23, 2466-2475.	4.4	17
14	The Prevalence of Autoimmune Diseases in Longstanding Diabetes: Results from the Canadian Study of Longevity in Adults with Type 1 Diabetes. Canadian Journal of Diabetes, 2021, 45, 512-518.e1.	0.8	4
15	Markers of Kidney Injury, Inflammation, and Fibrosis Associated With Ertugliflozin in Patients With CKD and Diabetes. Kidney International Reports, 2021, 6, 2095-2104.	0.8	23
16	Analysis of Prevalence, Magnitude and Timing of the Dawn Phenomenon in Adults and Adolescents With Type 1 Diabetes: Descriptive Analysis of 2 Insulin Pump Trials. Canadian Journal of Diabetes, 2020, 44, 229-235.	0.8	11
17	Quantitative sonographic evaluation of muscle thickness and fasciculation prevalence in healthy subjects. Muscle and Nerve, 2020, 61, 234-238.	2.2	13
18	The utility of a single simple question in the evaluation of patients with nondiabetic polyneuropathy. Muscle and Nerve, 2020, 61, 526-529.	2.2	4

#	Article	IF	CITATIONS
19	High fractional excretion of glycation adducts is associated with subsequent early decline in renal function in type 1 diabetes. Scientific Reports, 2020, 10, 12709.	3.3	10
20	18 - Empagliflozin Is Associated With Increased Plasma Lipid Metabolites in Type 1 Diabetes. Canadian Journal of Diabetes, 2020, 44, S7-S8.	0.8	0
21	Superiority of sonographic evaluation of contracted versus relaxed muscle thickness in motor neuron diseases. Clinical Neurophysiology, 2020, 131, 1480-1486.	1.5	10
22	Rapid Corneal Nerve Fiber Loss: A Marker of Diabetic Neuropathy Onset and Progression. Diabetes Care, 2020, 43, 1829-1835.	8.6	40
23	Randomized, controlled crossover study of IVIg for demyelinating polyneuropathy and diabetes. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, .	6.0	4
24	Sex differences in neuropathy & neuropathic pain: A brief report from the Phase 2 Canadian Study of Longevity in Type 1 Diabetes. Journal of Diabetes and Its Complications, 2019, 33, 107397.	2.3	8
25	Baseline Decrement in Patients with Mild Myasthenia Gravis Predicts Immunomodulation Treatment. Canadian Journal of Neurological Sciences, 2019, 46, 762-766.	0.5	1
26	European Federation of Neurological Societies cutoff values significantly reduce creatine kinase sensitivity for diagnosing neuromuscular disorders. Muscle and Nerve, 2019, 60, 748-752.	2.2	2
27	126 - Prevalence of Detectable C-peptide in Longstanding Type 1 Diabetes (T1D). Canadian Journal of Diabetes, 2019, 43, S43.	0.8	1
28	Muscle thickness measured by ultrasound is reduced in neuromuscular disorders and correlates with clinical and electrophysiological findings. Muscle and Nerve, 2019, 60, 687-692.	2.2	20
29	Elevated plasma cyclic guanosine monophosphate may explain greater efferent arteriolar tone in adults with longstanding type 1 diabetes: A brief report. Journal of Diabetes and Its Complications, 2019, 33, 547-549.	2.3	1
30	Estimating GFR by Serum Creatinine, Cystatin C, and β2-Microglobulin in Older Adults: Results From the Canadian Study of Longevity in Type 1 Diabetes. Kidney International Reports, 2019, 4, 786-796.	0.8	12
31	Risk factors for diabetic kidney disease in adults with longstanding type 1 diabetes: results from the Canadian Study of Longevity in Diabetes. Renal Failure, 2019, 41, 427-433.	2.1	4
32	Uric Acid Levels Correlate with Sensory Nerve Function in Healthy Subjects. Canadian Journal of Neurological Sciences, 2019, 46, 337-341.	0.5	4
33	Renal Hemodynamic Function and RAAS Activation Over the Natural History of Type 1 Diabetes. American Journal of Kidney Diseases, 2019, 73, 786-796.	1.9	15
34	Association between uric acid, renal haemodynamics and arterial stiffness over the natural history of type 1 diabetes. Diabetes, Obesity and Metabolism, 2019, 21, 1388-1398.	4.4	12
35	Bone mineral density in patients with longstanding type 1 diabetes: Results from the Canadian Study of Longevity in Type 1 Diabetes. Journal of Diabetes and Its Complications, 2019, 33, 107324.	2.3	21
36	Ultrasound-Assisted Lumbar Puncture in a Neuromuscular Clinic has a High Success Rate and Less Pain. Canadian Journal of Neurological Sciences, 2019, 46, 79-82.	0.5	6

#	Article	IF	CITATIONS
37	The relationships between markers of tubular injury and intrarenal haemodynamic function in adults with and without type 1 diabetes: Results from the Canadian Study of Longevity in Type 1 Diabetes. Diabetes, Obesity and Metabolism, 2019, 21, 575-583.	4.4	15
38	Retinopathy and RAAS Activation: Results From the Canadian Study of Longevity in Type 1 Diabetes. Diabetes Care, 2019, 42, 273-280.	8.6	16
39	Laboratory Abnormalities in Polyneuropathy and Electrophysiological Correlations. Canadian Journal of Neurological Sciences, 2018, 45, 346-349.	0.5	3
40	Sex differences in neuropathic pain intensity in diabetes. Journal of the Neurological Sciences, 2018, 388, 103-106.	0.6	38
41	Adiposity Impacts Intrarenal Hemodynamic Function in Adults With Long-standing Type 1 Diabetes With and Without Diabetic Nephropathy: Results From the Canadian Study of Longevity in Type 1 Diabetes. Diabetes Care, 2018, 41, 831-839.	8.6	13
42	Nerve function varies with hemoglobin A1c in controls and type 2 diabetes. Journal of Diabetes and Its Complications, 2018, 32, 424-428.	2.3	5
43	High frequency of MGUS in DSP. Muscle and Nerve, 2018, 57, 1018-1021.	2.2	Ο
44	Cramps frequency and severity are correlated with small and large nerve fiber measures in type 1 diabetes. Clinical Neurophysiology, 2018, 129, 122-126.	1.5	8
45	Toronto Clinical Neuropathy Score is valid for a wide spectrum of polyneuropathies. European Journal of Neurology, 2018, 25, 484-490.	3.3	23
46	Diabetes Care Disparities in Long-standing Type 1 Diabetes in Canada and the U.S.: A Cross-sectional Comparison. Diabetes Care, 2018, 41, 88-95.	8.6	17
47	The Relationships Between Retinopathy and Other Vascular Complications in Adults with Longstanding Diabetes: Results From the Canadian Study for Longevity in Type 1 Diabetes. Canadian Journal of Diabetes, 2018, 42, S50.	0.8	Ο
48	Atherosclerosis and Microvascular Complications: Results From the Canadian Study of Longevity in Type 1 Diabetes. Diabetes Care, 2018, 41, 2570-2578.	8.6	37
49	The median to ulnar cross-sectional surface area ratio in carpal tunnel syndrome. Clinical Neurophysiology, 2018, 129, 2239-2244.	1.5	7
50	Sex differences in neuropathic pain in longstanding diabetes: Results from the Canadian Study of Longevity in Type 1 Diabetes. Journal of Diabetes and Its Complications, 2018, 32, 660-664.	2.3	22
51	Corneal confocal microscopy for identification of diabetic sensorimotor polyneuropathy: a pooled multinational consortium study. Diabetologia, 2018, 61, 1856-1861.	6.3	103
52	Renin-angiotensin-aldosterone system activation in long-standing type 1 diabetes. JCI Insight, 2018, 3, .	5.0	38
53	Validity of a point-of-care nerve conduction device for polyneuropathy identification in older adults with diabetes: Results from the Canadian Study of Longevity in Type 1 Diabetes. PLoS ONE, 2018, 13, e0196647.	2.5	13
54	Repetitive nerve stimulation cutoff values for the diagnosis of myasthenia gravis. Muscle and Nerve, 2017, 55, 166-170.	2.2	27

#	Article	IF	CITATIONS
55	Peripheral nerve highâ€resolution ultrasound in diabetes. Muscle and Nerve, 2017, 55, 171-178.	2.2	64
56	Effect of omega-3 supplementation on neuropathy in type 1 diabetes. Neurology, 2017, 88, 2294-2301.	1.1	95
57	Neuropathy and presence of emotional distress and depression in longstanding diabetes: Results from the Canadian study of longevity in type 1 diabetes. Journal of Diabetes and Its Complications, 2017, 31, 1318-1324.	2.3	37
58	Dipeptidyl Peptidase 4 Inhibition Stimulates Distal Tubular Natriuresis and Increases in Circulating SDF-1α1-67 in Patients With Type 2 Diabetes. Diabetes Care, 2017, 40, 1073-1081.	8.6	82
59	Uric acid levels correlate with the severity of diabetic sensorimotor polyneuropathy. Journal of the Neurological Sciences, 2017, 379, 94-98.	0.6	12
60	Electrophysiological testing is correlated with myasthenia gravis severity. Muscle and Nerve, 2017, 56, 445-448.	2.2	19
61	Clinical characteristics, and impairment and disability scale scores for different CIDP Disease Activity Status classes. Journal of the Neurological Sciences, 2017, 372, 223-227.	0.6	13
62	Response to Comment on Lovshin et al. Dipeptidyl Peptidase 4 Inhibition Stimulates Distal Tubular Natriuresis and Increases in Circulating SDF-11± 1-67 in Patients With Type 2 Diabetes. Diabetes Care 2017;40:1073-1081. Diabetes Care, 2017, 40, e159-e160.	8.6	0
63	Agreement between automated and manual quantification of corneal nerve fiber length: Implications for diabetic neuropathy research. Journal of Diabetes and Its Complications, 2017, 31, 1066-1073.	2.3	26
64	Exploring the optimal diagnostic threshold value of corneal nerve fibre length (CNFL) for diabetic neuropathy (DN) identification. Canadian Journal of Diabetes, 2017, 41, S62.	0.8	1
65	Lower corneal nerve fibre length identifies diabetic neuropathy in older adults with diabetes: results from the Canadian Study of Longevity in Type 1 Diabetes. Diabetologia, 2017, 60, 2529-2531.	6.3	14
66	The sensitivity and specificity of the neurological examination in polyneuropathy patients with clinical and electrophysiological correlations. PLoS ONE, 2017, 12, e0171597.	2.5	21
67	Reference values for ultrasonograpy of peripheral nerves. Muscle and Nerve, 2016, 53, 538-544.	2.2	66
68	Prevalence of Insulin Pump Therapy and Its Association with Measures of Glycemic Control: Results from the Canadian Study of Longevity in Type 1 Diabetes. Diabetes Technology and Therapeutics, 2016, 18, 298-307.	4.4	25
69	Disease activity in chronic inflammatory demyelinating polyneuropathy. Journal of the Neurological Sciences, 2016, 369, 204-209.	0.6	11
70	Frequent laboratory abnormalities in CIDP patients. Muscle and Nerve, 2016, 53, 862-865.	2.2	18
71	Cardiovascular disease guideline adherence and self-reported statin use in longstanding type 1 diabetes: results from the Canadian study of longevity in diabetes cohort. Cardiovascular Diabetology, 2016, 15, 14.	6.8	29
72	Validation of cooling detection threshold as a marker of sensorimotor polyneuropathy in type 2 diabetes. Journal of Diabetes and Its Complications, 2016, 30, 716-722.	2.3	20

#	Article	IF	CITATIONS
73	Commonly Measured Clinical Variables Are Not Associated With Burden of Complications in Long-standing Type 1 Diabetes: Results From the Canadian Study of Longevity in Diabetes. Diabetes Care, 2016, 39, e67-e68.	8.6	19
74	Single- and Dual-Hormone Artificial Pancreas for Overnight Glucose Control in Type 1 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 214-223.	3.6	75
75	Laser Doppler Flare Imaging and Quantitative Thermal Thresholds Testing Performance in Small and Mixed Fiber Neuropathies. PLoS ONE, 2016, 11, e0165731.	2.5	33
76	Elevated Vibration Perception Thresholds in CIDP Patients Indicate More Severe Neuropathy and Lower Treatment Response Rates. PLoS ONE, 2015, 10, e0139689.	2.5	8
77	Reproducibility of In Vivo Corneal Confocal Microscopy Using an Automated Analysis Program for Detection of Diabetic Sensorimotor Polyneuropathy. PLoS ONE, 2015, 10, e0142309.	2.5	37
78	Cardiac Autonomic Neuropathy and Early Progressive Renal Decline in Patients with Nonmacroalbuminuric Type 1 Diabetes. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 1136-1144.	4.5	41
79	Treatment responsiveness in CIDP patients with diabetes is associated with unique electrophysiological characteristics, and not with common criteria for CIDP. Expert Review of Clinical Immunology, 2015, 11, 537-546.	3.0	13
80	Impact of glycemia on survival of glioblastoma patients treated with radiation and temozolomide. Journal of Neuro-Oncology, 2015, 124, 119-126.	2.9	67
81	Normative Values for Corneal Nerve Morphology Assessed Using Corneal Confocal Microscopy: A Multinational Normative Data Set. Diabetes Care, 2015, 38, 838-843.	8.6	150
82	Evaluation of a Clinical Tool to Test and Adjust the Programmed Overnight Basal Profiles for Insulin Pump Therapy: A Pilot Study. Canadian Journal of Diabetes, 2015, 39, 364-372.	0.8	4
83	InÂVivo Corneal Confocal Microscopy and Prediction ofÂFuture-Incident Neuropathy in Type 1 Diabetes: AÂPreliminaryÂLongitudinal Analysis. Canadian Journal of Diabetes, 2015, 39, 390-397.	0.8	57
84	Validation of Cooling Detection Threshold as a Marker of Sensorimotor Polyneuropathy in Type 2 Diabetes. Canadian Journal of Diabetes, 2015, 39, 542.	0.8	0
85	Reproducibility of In Vivo Corneal Confocal Microscopy Using an Automated Analysis Program for Detection of Diabetic Sensorimotor Polyneuropathy. Canadian Journal of Diabetes, 2015, 39, 543.	0.8	Ο
86	Treatment Responsiveness in CIDP Patients with Diabetes Is Associated with Higher Degrees of Demyelination. PLoS ONE, 2015, 10, e0139674.	2.5	9
87	Reliability and Validity of a Point-of-Care Sural Nerve Conduction Device for Identification of Diabetic Neuropathy. PLoS ONE, 2014, 9, e86515.	2.5	72
88	Response to Comment on Breiner et al. Does the Prevailing Hypothesis That Small-Fiber Dysfunction Precedes Large-Fiber Dysfunction Apply to Type 1 Diabetic Patients? Diabetes Care 2014;37:1418–1424. Diabetes Care, 2014, 37, e242-e242.	8.6	1
89	Does the Prevailing Hypothesis That Small-Fiber Dysfunction Precedes Large-Fiber Dysfunction Apply to Type 1 Diabetic Patients?. Diabetes Care, 2014, 37, 1418-1424.	8.6	105
90	Measurement of Cooling Detection Thresholds for Identification of Diabetic Sensorimotor Polyneuropathy in Type 1 Diabetes. PLoS ONE, 2014, 9, e106995.	2.5	14

#	Article	IF	CITATIONS
91	Conduction Slowing in Diabetic Sensorimotor Polyneuropathy. Diabetes Care, 2013, 36, 3684-3690.	8.6	63
92	The impact of common variation in the definition of diabetic sensorimotor polyneuropathy on the validity of corneal in vivo confocal microscopy in patients with type 1 diabetes: a brief report. Journal of Diabetes and Its Complications, 2013, 27, 240-242.	2.3	15
93	Comparison of diabetes patients with "demyelinating―diabetic sensorimotor polyneuropathy to those diagnosed with <scp>CIDP</scp> . Brain and Behavior, 2013, 3, 656-663.	2.2	21
94	Point Accuracy of Interstitial Continuous Glucose Monitoring During Exercise in Type 1 Diabetes. Diabetes Technology and Therapeutics, 2013, 15, 46-49.	4.4	47
95	Structure-Function Relationship Between Corneal Nerves and Conventional Small-Fiber Tests in Type 1 Diabetes. Diabetes Care, 2013, 36, 2748-2755.	8.6	83
96	Identification and Prediction of Diabetic Sensorimotor Polyneuropathy Using Individual and Simple Combinations of Nerve Conduction Study Parameters. PLoS ONE, 2013, 8, e58783.	2.5	58
97	Can Ultrasound of the Tibial Nerve Detect Diabetic Peripheral Neuropathy?. Diabetes Care, 2012, 35, 2575-2579.	8.6	92
98	Higher magnification lenses versus conventional lenses for evaluation of diabetic neuropathy by corneal in vivo confocal microscopy. Diabetes Research and Clinical Practice, 2012, 97, e37-e40.	2.8	12
99	Evaluation of Proxy Tests for SFSN: Evidence for Mixed Small and Large Fiber Dysfunction. PLoS ONE, 2012, 7, e42208.	2.5	14